共 8 条
Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment
被引:12
作者:
Gobert, D.
[1
]
Bouillet, L.
[2
]
Armengol, G.
[3
]
Coppo, P.
[4
]
Defendi, F.
[5
]
Du-Thanh, A.
[6
]
Hardy, G.
[7
]
Javaud, N.
[8
]
Jeandel, P-Y
[9
]
Launay, D.
[10
,11
,12
]
Panayotopoulos, V
[1
]
Pelletier, F.
[13
]
Boccon-Gibod, I
[2
]
Fain, O.
[1
]
机构:
[1] Sorbonne Univ, Serv Med Interne, Hop St Antoine, AP HP, F-75012 Paris, France
[2] Univ Grenoble Alpes, Ctr Natl Reference Angiaedemes CREAK, Serv Med Interne, CHU Grenoble Alpes, Grenoble, France
[3] Rouen Univ Hosp, Dept Internal Med, Rouen, France
[4] Sorbonne Univ, Hop St Antoine, AP HP, Serv Hematol, F-75012 Paris, France
[5] CHU Grenoble Alpes, Lab Immunol, Grenoble, France
[6] Univ Montpellier, Dept Dermatol, CHU Montpellier, Montpellier, France
[7] CHU Grenoble Alpes, UM Genet Mol Malad Hereditaires & Oncol, Grenoble, France
[8] Hop St Antoine, Serv Med Interne, 184 Rue Faubourg St Antoine, F-75012 Paris, France
[9] Univ Cote dAzur, Serv Med Interne, CHU Nice, Nice, France
[10] Univ Lille, U995, LIRIC Lille Inflammat Res Int Ctr, F-59000 Lille, France
[11] INSERM, U995, F-59000 Lille, France
[12] CHU Lille, Dept Med Interne & Immunol Clin, F-59000 Lille, France
[13] CHU Besancon, Unite Allergol, Serv Dermatol, Besancon, France
来源:
REVUE DE MEDECINE INTERNE
|
2020年
/
41卷
/
12期
关键词:
Bradykininin angioedema;
Acquired C1-inhibitor deficiency;
C1-inhibitor;
Bradykinin;
HEREDITARY;
D O I:
10.1016/j.revmed.2020.06.010
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrumof bradykinin angioedemas. It usually occurs in subjects over 60 years old, and is mostly associated with a B-cell lymphoid hemopathy or a monoclonal gammopathy. The diagnosis relies on at least one angioedema episode, lastingmore than 24 h, and on the decrease of functional C1-inhibitor. LowC1q is observed in 90% of patients, and an anti C1-inhibitor antibody is found in 50% of patients. The treatment of severe attacks relies on icatibant or C1-inhibitor perfusions. Long term prophylaxis in patients with frequent attacks requires treatment of the associated hemopathy if so. In case of idiopathic angioedema, tranexamic acid and danazol may be used, provided that there is-no thrombophilia; as well as rituximab as second-line treatment. Inhibitors of kallikrein still need to be evaluated in this therapeutic indication. (C) 2020 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:838 / 842
页数:5
相关论文